I have tried to look for the mechanism of how methyl benzimidazol-2-yl-carbamate affects microtubules in eukaryotes, but what I found wasn't very useful:

  1. Quilan et al 1980 assert that it acts by inhibiting polymerization of microtubules rather than by directly depolymerizing them.
  2. In "The Cytoskeleton: A Target for Toxic Agents", it is mentioned that

..strains of Aspergillus that were resistant to the drug had a lower affinity for MBC in a binding assay, whereas super-sensitive strains had a higher affinity for the drug.

Any references would be appreciated.

In Summary: I would like to know how the drug MBC effects the depolymerization of microtubules in eukaryotic cells. I would also appreciate any scientific references.

  • $\begingroup$ Welcome to Biology Stack Exchange! I made a few edits to your post, you are welcomed to change it back to the original if you feel it better describes your question. $\endgroup$
    – L.B.
    Commented Oct 26, 2015 at 22:52

1 Answer 1


Carbendazim inhibits microtubule polymerization by directly binding to tubulin, preventing subunits from interacting. Therefore, mytotic spindle malforms and potentially causes aneuploidy in affected cells. Mechanisms of resistance are often shown to be changes in membrane permeability to the compound.

CARBENDAZIM (addendum)


You must log in to answer this question.

Not the answer you're looking for? Browse other questions tagged .